Stroke prevention: An opportunity for efficient utilization of health care resources during the coming decade

Stroke

Volumn 25, Issue 1, 1994, Pages 220-224

  Gorelick, Philip B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Costs and cost analysis; Prevention, primary; Risk factors

Indexed keywords

ALCOHOL CONSUMPTION; CIGARETTE SMOKING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; POPULATION RISK; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE;

CEREBROVASCULAR DISORDERS; EPIDEMIOLOGIC METHODS; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SERVICES; HUMAN; PREVENTIVE MEDICINE; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027982835     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/01.STR.25.1.220     Document Type: Article

References (37)

1. American Heart Association. 1992 Heart and Stroke Facts. Dallas, Texas, 1991, pp 1-48.
2. Gorelick PB. Epidemiologic contributions. In: Caplan LR, ed. Scientific Basis of Stroke and Its Treatment. Springer-Verlag (in press).
3. Gorelick PB. Degenerative diseases. Chicago Medicine. 1991;94:14-18.
4. Wolf PA, Belanger AJ, D’Agostino RB. Management of risk factors. Neurol Clin. 1992;10:177-191.
5. Wolf PA, D’Agostino RB, Belanger AJ. Predicting Stroke Risk. Monograph. Phase Five Communications, Inc, August 1992, pp 10-14.
6. Mausner JS, Kramer S. Mausner and Bahn Epidemiology-An Introductory Text. Philadelphia, Pa: WB Saunders Company; 1985:1-42.
7. Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J. 1981;282:1847-1850.
8. Dunbabin DW, Sandercock PAG. Preventing stroke by modification of risk factors. Stroke. 1990;21(suppl IV):IV-36-IV-39.
9. Sox HC. Screening for lipid disorders under health system reform. N Engl J Med. 1993;328:1269-1271.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;256:3255-3264.
11. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis. 1986;29(suppl 1):99-118.
12. MacMahon S, Peto R, Cutler JA, Collins R, Sorlie P, Neaton J, Abbot R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke and coronary heart disease: part I. Effects of prolonged differences in blood pressure - evidence from nine prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
13. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JD, Hennekens CH. Blood pressure, stroke and coronary heart disease: part II. Effects of short-term reductions in blood pressure and overview of the unconfounded randomized drug trials in an epidemiologic context. Lancet. 1990;335:827-838.
14. Bozzola FG, Gorelick PB, Jensen JM. Epidemiology of intracranial hemorrhage. Neuroimag Clin N Am. 1992;2:l-10.
15. Gorelick PB, Rodin MB, Lanzerberg P, Hier DB, Costigan J. Weekly alcohol consumption, cigarette smoking, and the risk of ischemic stroke: results of a case-control study at three urban medical centers in Chicago, Illinois. Neurology. 1989;39:339-343.
16. Longstreth WT, Nelson L, Koespel TD, vanBelle G. Risk factors for subarachnoid hemorrhage. Stroke. 1991;22:149.
17. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. Br Med J. 1989;298:787-794.
18. Wolf PA, D’Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA. 1988;259:1025-1029.
19. Gorelick PB. The status of alcohol as a risk factor for stroke. Stroke. 1989;20:1607-1610.
20. Camargo CA. Moderate alcohol consumption and stroke: the epidemiologic evidence. Stroke. 1989;20:1611-1626.
21. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904-910.
22. Salonen R, Seppanen K, Rauramaa R, Salonen JT. Prevalence of carotid atherosclerosis and serum lipid levels in eastern Finland. Atherosclerosis. 1988;8:788-792.
23. Tell GS, Gouse JR, Furberg CD. Relation between blood lipids, lipoproteins and cerebrovascular atherosclerosis: a review. Stroke. 1988;19:423-430.
24. Qizibash N, Duffy SW, Warlow CP, Mann J. Lipids are risk factors for ischemic stroke. Cerebrovasc Dis. 1992;2:127-136.
25. Dennis MS, Warlow CP. Stroke: incidence, risk factors and outcome. Br J Hosp Med. 1987;37:194-198.
26. Sytkowski PA, Kannel WB, D’Agostino RB. Changes in risk factors and decline in mortality from cardiovascular disease. N Engl J Med. 1990;322:1635-1641.
27. Anderson DC, the SPAF Investigators. Progress report of the Stroke Prevention in Atrial Fibrillation Study. Stroke. 1990; 21(suppl III):III-12-III-17.
28. SPAF Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990;322:863-868.
29. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effects of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
30. Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications of chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;1:175-179.
31. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med. 1911;325:445-453.
32. European Carotid Surgery Trialists’ Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet. 1991;337:1235-1243.
33. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
34. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
35. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke L-A. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992;305:1457-1460.
36. Laupacis A, Feeny D, Detsky AS, Tegwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
37. Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med. 1993;119:329-335.